secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aptevo Therapeutics Inc. (APVO)
CIK:        0001671584
Form:       8-K
Filed at:   2026-01-09T23:59:59+00:00
Accession:  0001193125-26-008318
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aptevo secures $60M equity line with Yorkville, extends funding runway into 2029
--------------------------------------------------------------------------------

- Enters $60M Standby Equity Purchase Agreement with Yorkville; minimal fees, no warrants.
- Company has right to sell shares at 96% of lowest 3-day VWAP; capped at ~199,466 shares without approval.
- Fully leveraged facility plus cash on hand expected to extend funding into 2029.
- Proceeds to support pipeline including mipletamig (CD123xCD3) in Phase 1b/2 frontline AML trial.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671584/000119312526008318/0001193125-26-008318-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671584/000119312526008318/apvo-20260108.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-008318

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer